Show simple item record

dc.contributor.authorReed, Grace
dc.date.accessioned2020-01-23T10:36:21Z
dc.date.available2020-01-23T10:36:21Z
dc.date.issued2019-04-08
dc.identifier.citationReed, G. 2019. Does digoxin cause more harm than good? Journal of Paramedic Practice, 11 (4), 165–170.en_US
dc.identifier.issn1759-1376
dc.identifier.issn2041-9457
dc.identifier.doi10.12968/jpar.2019.11.4.165
dc.identifier.urihttp://hdl.handle.net/20.500.12417/651
dc.description.abstractBackground: The most recent British National Formulary recommends digoxin therapy for patients with heart failure (HF) and/or supraventricular arrhythmias, particularly atrial fibrillation (AF) and atrial flutter. The positive inotropic and negative chronotropic effects of the drug are undoubtedly desirable when managing these conditions, yet the use of digoxin is decreasing in popularity among prescribers. Aim: The aim of this literature review is to evaluate the use of digoxin for treating HF and/or AF. It will highlight the benefits of digoxin as well as its potential risks. These should be considered by all prehospital staff when assessing patients who are prescribed digoxin. Conclusions: Digoxin has shown positive outcomes for reducing hospital admissions for patients with HF and/or AF. However, clinicians should be aware of the narrow therapeutic index, which results in a high incidence of digoxin toxicity. The adverse effects of digoxin use should be considered during prehospital assessment, inclusive of pro-arrhythmic and thromboembolic complications. Whether digoxin may result in harm depends on the age, underlying pathology and renal function of each individual patient. Abstract published with permission.
dc.language.isoenen_US
dc.subjectPharmacy and Pharmacologyen_US
dc.subjectHeart Failureen_US
dc.subjectCardiologyen_US
dc.subjectAtrial Fibrillationen_US
dc.subjectParamedic Prescribingen_US
dc.subjectEmergency Medical Servicesen_US
dc.titleDoes digoxin cause more harm than good?en_US
dc.typeJournal Article/Review
dc.source.journaltitleJournal of Paramedic Practiceen_US
rioxxterms.versionNAen_US
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
rioxxterms.licenseref.startdate2019-12-04
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2019-04-08
html.description.abstractBackground: The most recent British National Formulary recommends digoxin therapy for patients with heart failure (HF) and/or supraventricular arrhythmias, particularly atrial fibrillation (AF) and atrial flutter. The positive inotropic and negative chronotropic effects of the drug are undoubtedly desirable when managing these conditions, yet the use of digoxin is decreasing in popularity among prescribers. Aim: The aim of this literature review is to evaluate the use of digoxin for treating HF and/or AF. It will highlight the benefits of digoxin as well as its potential risks. These should be considered by all prehospital staff when assessing patients who are prescribed digoxin. Conclusions: Digoxin has shown positive outcomes for reducing hospital admissions for patients with HF and/or AF. However, clinicians should be aware of the narrow therapeutic index, which results in a high incidence of digoxin toxicity. The adverse effects of digoxin use should be considered during prehospital assessment, inclusive of pro-arrhythmic and thromboembolic complications. Whether digoxin may result in harm depends on the age, underlying pathology and renal function of each individual patient. Abstract published with permission.en_US


This item appears in the following Collection(s)

Show simple item record